Table 1 Clinical characteristics of enrolled individuals
ATB (n = 67) | MPE (n = 21) | LTBI (n = 20) | HC (n = 21) | P value | ||
|---|---|---|---|---|---|---|
PTB (n = 39) | TBP (n = 28) | |||||
Male/Female | 30/9 | 23/5 | 16/5 | 10/10 | 13/8 | 0.0992 |
Age, median (IQR) | 44 (28–62) | 48 (23–66) | 72 (63–78) | 53 (40–64) | 46 (27–65) | <0.0001 |
History of BCG vaccination, n (%) | 24 (61.5) | 19 (67.8) | 11 (52.4) | 15 (75.0) | 17 (80.9) | 0.2913 |
IGRA+, n (%) | / | / | / | 20 (100.0) | 0 (0) | / |
Sputum AFB smear or culture positive, n (%) | 35 (89.7) | 8 (28.6) | 0 | / | / | / |
1+ | 11 (28.2) | 7 (25.0) | 0 | / | / | / |
>1+ (2+, 3+, 4+) | 24 (61.5) | 1 (3.6) | 0 | / | / | / |
Cavity, n (%) | 19 (48.7) | 1 (3.6) | 0 | / | / | / |
M. tb detection in pleural effusion | ||||||
Confirmed TBP by pleural biopsy, n (%) | / | 8 (28.6) | 0 | / | / | / |
AFB smear or culture positive, n (%) | / | 3 (10.7) | 0 | / | / | / |
anti-TB therapy status at enrollment | ||||||
Naive, n (%) | 8 (20.5) | 23 (82.1) | / | / | / | / |
Days on anti-TB, median (IQR) | 2 (1–7) | 9 (5–12) | / | / | / | / |